Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Innoviva Inc    INVA

INNOVIVA INC (INVA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
14.86(c) 14.63(c) 14.11(c) 14.28(c) 14.19(c) Last
613 414 844 265 748 477 625 081 584 956 Volume
-0.34% -1.55% -3.55% +1.20% -0.63% Change
More quotes
Financials (USD)
Sales 2018 258 M
EBIT 2018 232 M
Net income 2018 220 M
Debt 2018 297 M
Yield 2018 -
Sales 2019 276 M
EBIT 2019 254 M
Net income 2019 273 M
Debt 2019 41,0 M
Yield 2019 -
P/E ratio 2018 7,10
P/E ratio 2019 5,56
EV / Sales2018 6,73x
EV / Sales2019 5,36x
Capitalization 1 440 M
More Financials
Company
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals.Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of Innoviva Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on INNOVIVA INC
07/13Free Technical Research on Insmed and Three More Biotech Equities
AC
06/19INNOVIVA : 6,764 Shares in Innoviva Inc (INVA) Purchased by SG Americas Securiti..
AQ
06/07GLAXOSMITHKLINE : GSK Submits Regulatory Application in Japan for Once-Daily Sin..
AQ
05/30INNOVIVA : Glaxo makes new drug application in Japan for COPD treatment, Trelegy..
AQ
05/30INNOVIVA : Immersion Signs License Agreement with Panasonic to Add Haptics to Au..
PU
05/28MANAGEMENT TRACKS : ISA, ImCheck, ArQule
AQ
05/23INNOVIVA, INC. : Change in Directors or Principal Officers, Financial Statements..
AQ
05/22INNOVIVA : Names Geoffrey Hulme as Interim Principal Executive Officer
BU
05/15INNOVIVA : Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Resul..
AQ
05/04INNOVIVA : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
More news
Sector news : Pharmaceuticals - NEC
10:43aCHINA'S LATEST CONSUMER SCANDAL : Unsafe Vaccines
DJ
08:16aSHIRE PLC SHIRE PLC : Notice Of Results
DJ
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
RE
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
07/18Innoviva Sees Unusually Large Options Volume $INVA  
07/06Innoviva $INVA Rating Increased to Hold at BidaskClub  
06/30Innoviva $INVA Lowered to Sell at ValuEngine  
06/30Want the latest upgrades & downgrades for $TYL $INVA $RDN $ARW $OGE? Chec.. 
06/28Stifel Nicolaus Reiterates “Hold” Rating for Innoviva $INVA  
More tweets
Qtime:40
News from SeekingAlpha
06/16Forensic Value Algorithm Stock Selections - June 
06/12FDA Ad Com approaches for PneumRx endobronchial coil 
05/31YOUR DAILY PHARMA SCOOP : 4 NDAs... CPRX, EXEL, ALPMY, ACOR 
05/29GSK submits regulatory application in Japan for FF/UMEC/VI for patients with .. 
05/22New interim chief at Innoviva 
Chart INNOVIVA INC
Duration : Period :
Innoviva Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Technical analysis trends INNOVIVA INC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 15,0 $
Spread / Average Target 5,7%
EPS Revisions
Managers
NameTitle
Geoffrey Hulme Chief Executive Officer
Odysseas Demosthenes Kostas Chairman
Eric d'Esparbes Chief Financial Officer & Senior Vice President
Theodore J. Witek Chief Scientific Officer & Senior Vice President
Catherine J. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INNOVIVA INC0.00%1 449
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-0.24%206 705
ROCHE HOLDING LTD.-5.07%200 737
MERCK AND COMPANY11.11%168 171